When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.
02 Jul 2019
THE MONTHLY July 2019
Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 311 | Allergy Therapeutics plc (AGY:LON), 2.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,070 | City of London Investment Group PLC (CLIG:LON), 328 | DP Poland PLC (DPP:LON), 10.5 | Gateley (Holdings) Plc (GTLY:LON), 120 | Koovs (KOOV:LON), 0 | Lightwaverf (LWRF:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 218 | Palace Capital plc (PCA:LON), 236 | Primary Health Properties PLC (PHP:LON), 90.8 | R.E.A. Holdings plc (RE:LON), 73.5 | Redx Pharma Plc (REDX:LON), 10.2 | RM Infrastructure Income PLC GBP (RMII:LON), 75.5 | Shield Therapeutics Plc (STX:LON), 1.3 | Tissue Regenix Group plc (TRX:LON), 61.5 | Titon Holdings Plc (TON:LON), 85.0 | Urban Logistics REIT plc (SHED:LON), 110 | Volta Finance Limited (VTA:LON), 504 | Warpaint London PLC (W7L:LON), 495 | ValiRx PLC (VAL:LON), 3.4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
THE MONTHLY July 2019
Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 311 | Allergy Therapeutics plc (AGY:LON), 2.8 | Arbuthnot Banking Group PLC (ARBB:LON), 1,070 | City of London Investment Group PLC (CLIG:LON), 328 | DP Poland PLC (DPP:LON), 10.5 | Gateley (Holdings) Plc (GTLY:LON), 120 | Koovs (KOOV:LON), 0 | Lightwaverf (LWRF:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 218 | Palace Capital plc (PCA:LON), 236 | Primary Health Properties PLC (PHP:LON), 90.8 | R.E.A. Holdings plc (RE:LON), 73.5 | Redx Pharma Plc (REDX:LON), 10.2 | RM Infrastructure Income PLC GBP (RMII:LON), 75.5 | Shield Therapeutics Plc (STX:LON), 1.3 | Tissue Regenix Group plc (TRX:LON), 61.5 | Titon Holdings Plc (TON:LON), 85.0 | Urban Logistics REIT plc (SHED:LON), 110 | Volta Finance Limited (VTA:LON), 504 | Warpaint London PLC (W7L:LON), 495 | ValiRx PLC (VAL:LON), 3.4
- Published:
02 Jul 2019 -
Author:
Brian Moretta -
Pages:
37
When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.